Abstract
This evaluation of a Cochrane-review including five clinical trials of good methodological quality indicates that the antiangiogenic therapeutic agents, pegaptanib and ranibizumab, are effective treatment strategies for neovascular Age-Related Macular Degeneration (AMD). The review does not include a direct comparison or an indirect statistical comparison between the two antiangiogenic agents. In clinical practice ranibizumab compared to pegaptanib is the drug of choice because of cost-utility analysis and the number of patients gaining visual acuity.
| Bidragets oversatte titel | [Treatment of wet age-related macular degeneration with vascular endothelial growth factor. A survey of a Cochrane review] |
|---|---|
| Originalsprog | Dansk |
| Tidsskrift | Ugeskrift for Laeger |
| Vol/bind | 171 |
| Udgave nummer | 47 |
| Sider (fra-til) | 3435-7 |
| Antal sider | 3 |
| Status | Udgivet - 16 nov. 2009 |
Emneord
- Aged
- Angiogenesis Inhibitors
- Antibodies, Monoclonal
- Aptamers, Nucleotide
- Evidence-Based Medicine
- Humans
- Porphyrins
- Treatment Outcome
- Vascular Endothelial Growth Factor A
- Wet Macular Degeneration